The PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diabetics, moves into next phase
LUND, SWEDEN – Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly onset type 2 diabetics is moving into the next phase. Samples with the associated clinical data have been transferred to Immunovia from Lund University Diabetes Center (LUDC). During the second half of 2022 the samples will be analyzed as the next phase of the development plan for this large risk group. “We are entering into a decisive phase of the PanDIA study, aiming to give another substantial risk group for pancreatic cancer the ability to get access to early